Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease

Taylor R. Hendershott, Delphine Zhu, Seoni Llanes, Cyrus P. Zabetian, Joseph Quinn, Karen L. Edwards, James B. Leverenz, Thomas Montine, Brenna Cholerton, Kathleen L. Poston

Research output: Contribution to journalArticle

Abstract

Background: Clinicians and researchers commonly use global cognitive assessments to screen for impairment. Currently there are no published studies directly comparing the sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. The objective of this study was to identify the relative sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. Methods: The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 were administered to training and validation cohorts. Cutoff scores were determined within the training cohort (n = 85) to optimize sensitivity and specificity for cognitive impairment and were applied to an independent validation cohort (n = 521). Results: The Montreal Cognitive Assessment was consistently sensitive across training and validation cohorts (90.0% and 80.3%, respectively), whereas the Mattis Dementia Rating Scale-2 was not (87.5% and 60.3%, respectively). In individual domains, the Montreal Cognitive Assessment remained sensitive to memory and visuospatial impairments (91.9% and 87.8%, respectively), whereas the Mattis Dementia Rating Scale-2 was sensitive to executive impairments (86.2%). Conclusion: The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 demonstrated individual strengths. Future work should focus on developing domain-specific cognitive screening tools for PD.

Original languageEnglish (US)
JournalMovement Disorders
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Parkinson Disease
Dementia
Sensitivity and Specificity
Research Personnel

Keywords

  • cognitive impairment
  • Mattis Dementia Rating Scale-2
  • Montreal Cognitive Assessment
  • Parkinson's disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Hendershott, T. R., Zhu, D., Llanes, S., Zabetian, C. P., Quinn, J., Edwards, K. L., ... Poston, K. L. (Accepted/In press). Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.27575

Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease. / Hendershott, Taylor R.; Zhu, Delphine; Llanes, Seoni; Zabetian, Cyrus P.; Quinn, Joseph; Edwards, Karen L.; Leverenz, James B.; Montine, Thomas; Cholerton, Brenna; Poston, Kathleen L.

In: Movement Disorders, 01.01.2018.

Research output: Contribution to journalArticle

Hendershott, TR, Zhu, D, Llanes, S, Zabetian, CP, Quinn, J, Edwards, KL, Leverenz, JB, Montine, T, Cholerton, B & Poston, KL 2018, 'Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease', Movement Disorders. https://doi.org/10.1002/mds.27575
Hendershott, Taylor R. ; Zhu, Delphine ; Llanes, Seoni ; Zabetian, Cyrus P. ; Quinn, Joseph ; Edwards, Karen L. ; Leverenz, James B. ; Montine, Thomas ; Cholerton, Brenna ; Poston, Kathleen L. / Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease. In: Movement Disorders. 2018.
@article{d0c40913ff454391904d222782b3d000,
title = "Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease",
abstract = "Background: Clinicians and researchers commonly use global cognitive assessments to screen for impairment. Currently there are no published studies directly comparing the sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. The objective of this study was to identify the relative sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. Methods: The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 were administered to training and validation cohorts. Cutoff scores were determined within the training cohort (n = 85) to optimize sensitivity and specificity for cognitive impairment and were applied to an independent validation cohort (n = 521). Results: The Montreal Cognitive Assessment was consistently sensitive across training and validation cohorts (90.0{\%} and 80.3{\%}, respectively), whereas the Mattis Dementia Rating Scale-2 was not (87.5{\%} and 60.3{\%}, respectively). In individual domains, the Montreal Cognitive Assessment remained sensitive to memory and visuospatial impairments (91.9{\%} and 87.8{\%}, respectively), whereas the Mattis Dementia Rating Scale-2 was sensitive to executive impairments (86.2{\%}). Conclusion: The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 demonstrated individual strengths. Future work should focus on developing domain-specific cognitive screening tools for PD.",
keywords = "cognitive impairment, Mattis Dementia Rating Scale-2, Montreal Cognitive Assessment, Parkinson's disease",
author = "Hendershott, {Taylor R.} and Delphine Zhu and Seoni Llanes and Zabetian, {Cyrus P.} and Joseph Quinn and Edwards, {Karen L.} and Leverenz, {James B.} and Thomas Montine and Brenna Cholerton and Poston, {Kathleen L.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/mds.27575",
language = "English (US)",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease

AU - Hendershott, Taylor R.

AU - Zhu, Delphine

AU - Llanes, Seoni

AU - Zabetian, Cyrus P.

AU - Quinn, Joseph

AU - Edwards, Karen L.

AU - Leverenz, James B.

AU - Montine, Thomas

AU - Cholerton, Brenna

AU - Poston, Kathleen L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Clinicians and researchers commonly use global cognitive assessments to screen for impairment. Currently there are no published studies directly comparing the sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. The objective of this study was to identify the relative sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. Methods: The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 were administered to training and validation cohorts. Cutoff scores were determined within the training cohort (n = 85) to optimize sensitivity and specificity for cognitive impairment and were applied to an independent validation cohort (n = 521). Results: The Montreal Cognitive Assessment was consistently sensitive across training and validation cohorts (90.0% and 80.3%, respectively), whereas the Mattis Dementia Rating Scale-2 was not (87.5% and 60.3%, respectively). In individual domains, the Montreal Cognitive Assessment remained sensitive to memory and visuospatial impairments (91.9% and 87.8%, respectively), whereas the Mattis Dementia Rating Scale-2 was sensitive to executive impairments (86.2%). Conclusion: The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 demonstrated individual strengths. Future work should focus on developing domain-specific cognitive screening tools for PD.

AB - Background: Clinicians and researchers commonly use global cognitive assessments to screen for impairment. Currently there are no published studies directly comparing the sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. The objective of this study was to identify the relative sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. Methods: The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 were administered to training and validation cohorts. Cutoff scores were determined within the training cohort (n = 85) to optimize sensitivity and specificity for cognitive impairment and were applied to an independent validation cohort (n = 521). Results: The Montreal Cognitive Assessment was consistently sensitive across training and validation cohorts (90.0% and 80.3%, respectively), whereas the Mattis Dementia Rating Scale-2 was not (87.5% and 60.3%, respectively). In individual domains, the Montreal Cognitive Assessment remained sensitive to memory and visuospatial impairments (91.9% and 87.8%, respectively), whereas the Mattis Dementia Rating Scale-2 was sensitive to executive impairments (86.2%). Conclusion: The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 demonstrated individual strengths. Future work should focus on developing domain-specific cognitive screening tools for PD.

KW - cognitive impairment

KW - Mattis Dementia Rating Scale-2

KW - Montreal Cognitive Assessment

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=85058171806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058171806&partnerID=8YFLogxK

U2 - 10.1002/mds.27575

DO - 10.1002/mds.27575

M3 - Article

C2 - 30776152

AN - SCOPUS:85058171806

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

ER -